Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Avian coronavirus vaccination strategy shows promise
The new vaccination strategy could improve chicken welfare and has broader benefits for vaccine development.

The method could reduce the burden of IBV on the poultry industry.

Researchers at the Pirbright Institute are exploring new strategies for the development of an infectious bronchitis virus (IBV) vaccine.

In the journal Virology, scientists explain how they used ‘targeted attenuation’ to make specific modifications to weaken the virus, without compromising its ability to stimulate immunity.

It is hoped the method could reduce the burden of IBV on the poultry industry, improve welfare and protect food security. It may also have broader benefits for vaccine development.

Dr Erica Bickerton explains: “By using targeted attenuation we can develop vaccines that are more effective and adaptable to new strains. It also opens up the possibility of developing vaccines against other coronaviruses.”

IBV, also known as avian coronavirus, is a respiratory condition that leads to a loss of weight and drop in egg production. It has also raised a number of welfare concerns. 

One of the biggest challenges facing the poultry industry, the disease is currently managed via a combination of live attenuated vaccines and inactivated vaccines.

The live vaccines use a weakened form of the virus, created by repeatedly ‘growing’ the virus in eggs until it loses virulence. However, because this relies on random genetic mutations that occasionally compromise efficacy of the vaccine, it can be unreliable.

The method is also time-consuming, meaning that it’s unsuitable for responding to new or emerging strains of the virus.

Vaccines against other coronaviruses, such as SARS-CoV-2, primarily target the Spike (S) protein. However, the proven ineffectiveness of this approach has underscored the need for alternative strategies. 

In the study, the team examined a different target — the non-structural protein (nsp3), specifically a region called the macrodomain. By introducing targeted mutations within this protein, they identified genetic changes that could weaken the virus while maintaining its capacity to induce immunity. 

The study identifies targets conserved across IBV strains and the coronovirus family, suggesting a universal approach to vaccine development through rational attenuation.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.